Literature DB >> 29862466

Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.

Agathe Béranger1,2, Sihem Benaboud3,4, Saïk Urien5,3, Florence Moulin6, Emmanuelle Bille7, Fabrice Lesage6, Yi Zheng4, Mathieu Genuini6, Inès Gana4, Sylvain Renolleau6, Déborah Hirt3,4, Jean-Marc Tréluyer5,3,4, Mehdi Oualha3,6.   

Abstract

BACKGROUND: Critically ill children frequently display observed alterations of pharmacokinetic (PK) parameters, leading to a reduction in β-lactam concentrations. This study aimed to develop a PK population model for piperacillin in order to optimize individual dosing regimens.
METHODS: All children aged ≤ 18 years, weighing more than 2.5 kg, and receiving piperacillin infusions were included in this study. Piperacillin was quantified by high-performance liquid chromatography, and PK were described using the non-linear mixed-effect modeling software MONOLIX. Monte Carlo simulations were used to optimize dosing regimens in order to attain two PK targets: 50% fT>MIC and 100% fT>MIC.
RESULTS: We included 50 children with a median (range) postnatal age of 2.3 years (0.1-18), body weight (BW) of 11.9 kg (2.7-50), Pediatric Logistic Organ Dysfunction-2 (PELOD-2) severity score of 4 (0-16), and estimated glomerular filtration rate (eGFR) of 142 mL.min-1.1.73 m-2 (29-675). A one-compartment model with first-order elimination adequately described the data. Median (range) values for piperacillin clearance (CL) and volume of distribution were 3 L.h-1 (0.71-10) and 0.33 L.kg-1 (0.21-0.86), respectively. BW was integrated with the allometric relationship. eGFR and PELOD-2 severity score were the covariates explaining between-subject variability in CL and volume, respectively. According to the simulations, extended and continuous infusion provided the highest probability of reaching the target of 50% fT>MIC and 100% fT>MIC for normal and augmented renal clearance, respectively.
CONCLUSIONS: Unlike standard intermittent piperacillin dosing regimens, extended and continuous infusion allows the PK targets to be reached, for children with normal or augmented renal clearance. TRIAL REGISTRATION NUMBER: Registered at http://www.clinicaltrials.gov (NCT02539407).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29862466     DOI: 10.1007/s40262-018-0682-1

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  40 in total

Review 1.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

2.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Daily serum piperacillin monitoring is advisable in critically ill patients.

Authors:  Nicolas Blondiaux; Frédéric Wallet; Raphaël Favory; Thierry Onimus; Saad Nseir; René J Courcol; Alain Durocher; Micheline Roussel-Delvallez
Journal:  Int J Antimicrob Agents       Date:  2010-03-11       Impact factor: 5.283

4.  Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients.

Authors:  Jean-Marie Conil; Bernard Georges; Olivier Mimoz; Eric Dieye; Stéphanie Ruiz; Pierre Cougot; Kamran Samii; Georges Houin; Sylvie Saivin
Journal:  Intensive Care Med       Date:  2006-10-24       Impact factor: 17.440

5.  Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.

Authors:  Jeffrey J Cies; Venkat Shankar; Christine Schlichting; Joseph L Kuti
Journal:  Pediatr Infect Dis J       Date:  2014-02       Impact factor: 2.129

Review 6.  International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.

Authors:  Brahm Goldstein; Brett Giroir; Adrienne Randolph
Journal:  Pediatr Crit Care Med       Date:  2005-01       Impact factor: 3.624

7.  Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.

Authors:  Jason A Roberts; Rob Boots; Claire M Rickard; Peter Thomas; Jo Quinn; Darren M Roberts; Brent Richards; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2006-11-28       Impact factor: 5.790

Review 8.  Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Kazuro Ikawa; Konstantinos Z Vardakas
Journal:  Clin Infect Dis       Date:  2012-10-16       Impact factor: 9.079

9.  The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children.

Authors:  Ann Versporten; Julia Bielicki; Nico Drapier; Mike Sharland; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2016-01-08       Impact factor: 5.790

10.  Human renal function maturation: a quantitative description using weight and postmenstrual age.

Authors:  Malin M Rhodin; Brian J Anderson; A Michael Peters; Malcolm G Coulthard; Barry Wilkins; Michael Cole; Etienne Chatelut; Anders Grubb; Gareth J Veal; Michael J Keir; Nick H G Holford
Journal:  Pediatr Nephrol       Date:  2008-10-10       Impact factor: 3.714

View more
  16 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

2.  Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.

Authors:  Céline Thibault; Jean Lavigne; Catherine Litalien; Nastya Kassir; Yves Théorêt; Julie Autmizguine
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.

Authors:  Sean N Avedissian; Roxane Rohani; John Bradley; Jennifer Le; Nathaniel J Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

5.  Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?

Authors:  Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2018-10-29       Impact factor: 3.714

6.  Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients.

Authors:  Hiie Soeorg; Aveli Noortoots; Maarja Karu; Kadri Saks; Jana Lass; Irja Lutsar; Lenne-Triin Kõrgvee
Journal:  Eur J Clin Pharmacol       Date:  2022-03-11       Impact factor: 2.953

7.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Authors:  Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

8.  Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Authors:  Anders Thorsted; Anders N Kristoffersson; Sabine F Maarbjerg; Henrik Schrøder; Mikala Wang; Birgitte Brock; Elisabet I Nielsen; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

9.  Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.

Authors:  D Hirt; M Oualha; B Pasquiers; S Blanot; R Rubinstazjn; C Glorion; S El Messaoudi; D Drummond; V Lopez; J Toubiana; A Béranger; Sana Boujaafar; Yi Zheng; Carmen Capito; S Winter; P L Léger; R Berthaud; Inès Gana; F Foissac; J M Tréluyer; N Bouazza; S Benaboud
Journal:  Eur J Clin Pharmacol       Date:  2021-06-23       Impact factor: 2.953

Review 10.  Optimizing the Use of Antibiotic Agents in the Pediatric Intensive Care Unit: A Narrative Review.

Authors:  Jef Willems; Eline Hermans; Petra Schelstraete; Pieter Depuydt; Pieter De Cock
Journal:  Paediatr Drugs       Date:  2020-11-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.